The Board of Directors is pleased to present the Management Discussion and Analysis Report of Q-Line Biotech Limited for the financial year ended March 31, 2026, which forms an integral part of this Annual Report.
This Report provides a comprehensive analysis of the Companys business and operating environment, including the global and Indian economic scenario, industry structure and developments, operational and financial performance, opportunities and threats, risks and concerns, internal control systems and their adequacy, key financial ratios, human resources, and the Companys outlook for the future.
The Management Discussion and Analysis has been prepared in accordance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and is intended to provide shareholders and other stakeholders with a balanced and informed assessment of the Companys performance, business environment and future growth prospects.
GLOBAL ECONOMY
The global economy remained resilient during FY 2025-26 despite geopolitical tensions, evolving trade policies, inflationary pressures and volatility in commodity and financial markets. Global growth continued to be supported by domestic consumption, investment and technological advancement, while uncertainties relating to international trade, supply chains and monetary policies remained key factors influencing the global business environment.
The global healthcare sector continues to benefit from increasing healthcare expenditure, ageing populations, rising incidence of chronic diseases and greater emphasis on preventive healthcare and early diagnosis. Technological advancements, automation and increasing adoption of affordable and decentralised diagnostic solutions are also contributing to the long-term growth of the healthcare and diagnostics ecosystem.
INDIAN ECONOMY
The Indian economy continued to demonstrate strong resilience during FY 2025-26, supported by domestic consumption, investment, infrastructure development, manufacturing activity and growth in the services sector. Indias continued economic expansion, increasing formalisation and improving healthcare infrastructure have created a favourable environment for the healthcare sector.
Healthcare expenditure in India is witnessing structural growth, driven by increasing health awareness, rising prevalence of chronic and lifestyle-related diseases, expansion of hospitals and diagnostic centres and improving healthcare access across Tier-II and Tier-III cities. The increasing focus on preventive healthcare, early diagnosis, indigenous manufacturing and technological advancement is expected to support sustained growth in the diagnostics and medical-device ecosystem.
INDUSTRY STRUCTURE AND DEVELOPMENTS
The Indian In-Vitro Diagnostics (IVD) industry forms an integral part of the healthcare ecosystem, supporting the screening, diagnosis and monitoring of various diseases. The industry comprises reagents and diagnostic kits, analysers, point-of-care devices, molecular diagnostics, immunodiagnostics, haematology and clinical chemistry solutions.
The industry continues to witness structural growth, supported by increasing healthcare awareness, rising prevalence of chronic and lifestyle-related diseases, expansion of hospitals and diagnostic laboratories, greater emphasis on preventive healthcare and increasing adoption of technology and automation.
The Indian IVD market is characterised by a significant contribution from reagents and diagnostic kits, reflecting the recurring nature of diagnostic testing. The industry is also witnessing increasing adoption of indigenous manufacturing, automation and disposable diagnostic products, supported by growing demand for accessible, accurate and cost-effective diagnostic solutions.
RESEARCH AND DEVELOPMENT, TECHNOLOGY AND INNOVATION
Research and development continues to be an important part of the Companys business strategy. The Companys R&D activities are focused on the development of new diagnostic products, improvement and validation of existing products, formulation development, optimisation of manufacturing processes and adaptation of technologies to Indian market requirements.
The Company continues to strengthen its indigenous capabilities in diagnostic reagents, kits and instruments, while leveraging technical collaborations and technology partnerships, wherever appropriate. These initiatives are aimed at developing reliable, affordable and scalable diagnostic solutions while maintaining product quality, consistency and regulatory compliance.
MANUFACTURING CAPABILITIES AND CAPACITY EXPANSION
Manufacturing remains a key focus area of the Companys growth strategy. During the financial year under review, the Company further strengthened its manufacturing infrastructure with the commissioning of its fourth manufacturing unit situated at C-42 Industrial Area Amausi, Nadarganj, Lucknow, 226008.
The facility has added manufacturing capabilities for clinical chemistry reagents, rapid/ELISA kits, glucometer devices and glucometer strips, thereby strengthening the Companys indigenous manufacturing capabilities and supporting its ability to cater to increasing demand for diagnostic products.
The Company has also continued to pursue expansion of its manufacturing capabilities, including the proposed manufacturing facility at YEIDA, which is intended to support the manufacture of IVD medical devices, reagents and consumables, subject to applicable approvals and implementation requirements.
The Companys continued investment in manufacturing infrastructure is expected to support capacity enhancement, greater value addition, product availability and the increasing contribution of manufactured products to the Companys overall business.
OPPORTUNITIES AND THREATS
Opportunities
1. Growing Diagnostic Market
Increasing healthcare awareness, rising prevalence of chronic and lifestyle-related diseases, expansion of diagnostic infrastructure and greater emphasis on preventive healthcare are expected to support sustained growth in the IVD market.
2. Increasing Indigenous Manufacturing
The growing focus on domestic manufacturing of medical devices and diagnostic products presents an opportunity to expand the portfolio of locally manufactured reagents, kits and diagnostic instruments and reduce dependence on imported products.
3. Expansion of Reagents and Consumables
The increasing installed base of diagnostic instruments provides an opportunity for recurring demand for compatible reagents, kits and consumables. The growing adoption of automated and point-of-care testing further expands the addressable market.
4. Domestic and International Expansion
Increasing penetration of diagnostic services in Tier-II and Tier-III cities, together with opportunities in international markets and CMO/CDMO arrangements, provides scope for geographic and business diversification.
5. Manufacturing-led Growth:
The expansion of indigenous manufacturing capabilities provides an opportunity to increase value addition, improve product availability and strengthen the Companys position in the domestic IVD market.
6. Recurring Revenue from Installed Base:
The growing installed base of diagnostic instruments provides an opportunity to increase recurring demand for associated reagents, kits and consumables, supporting greater customer engagement and revenue visibility.
THREATS
1. Intense Competition
The IVD industry is highly competitive, with the presence of established domestic and multinational players. Competitive pricing, technological capabilities, product range and distribution strength may affect market share and margins.
2. Regulatory and Technological Changes
The industry is subject to evolving regulatory and quality requirements. Rapid technological developments may also require continuous investment in R&D, product development and manufacturing capabilities.
3. Supply Chain and Cost Volatility
Fluctuations in raw-material and component prices, dependence on certain imported inputs, foreign exchange movements and disruptions in global supply chains may affect product costs and operating margins.
4. Working Capital and Customer Risks
The business requires effective management of inventory and trade receivables. Delays in collections, changes in customer procurement patterns or dependence on distributors may affect liquidity and operating performance.
SEGMENT WISE OR PRODDUCT WISE PERORMANCE
The Company operates across the In-Vitro Diagnostics (IVD) and medical diagnostics industry, with its business comprising indigenous manufacturing of diagnostic reagents, consumables and instruments, along with sourcing, distribution and servicing of diagnostic products and equipment.
Its portfolio covers Clinical Chemistry, Haematology, Molecular Diagnostics, Point-of-Care Testing, Rapid Tests, ELISA and Special Diagnostics, including reagents, diagnostic kits, analysers, instruments and related consumables.
During the year under review, the Company continued to strengthen its manufacturing capabilities, product portfolio and distribution network, with increasing focus on indigenous manufacturing and recurring revenue opportunities from reagents, kits and consumables.
Segment-wise Financial Performance
in Lakhs
| Particulars | FY 2025-26 | FY 2024-25 | Change |
| Manufactured Products | 23,022.65 | 16,897.01 | +36.25% |
| Traded Products | 11,093.19 | 14,410.42 | -23.02% |
| Total Revenue from Operations | 34,115.84 | 31,307.43 | +8.97% |
The manufactured products business contributed approximately 67.49% of revenue from operations during FY 2025-26, compared with approximately 53.97% in the previous year, reflecting the Companys increasing focus on its manufacturing-led business.
At the segment-result level, manufactured products generated 11,597.20 lakh, compared with 7,659.57 lakh in FY 2024-25, while traded products generated 4,246.36 lakh, compared with 4,507.94 lakh in the previous year.
OUTLOOK
The outlook for the Indian IVD and diagnostics industry remains positive, supported by increasing diagnostic awareness, rising healthcare expenditure, expansion of healthcare infrastructure and growing demand for reliable, affordable and technologically advanced diagnostic solutions.
The Company is expected to benefit from the continued expansion of its manufacturing capabilities and product portfolio, with particular focus on indigenous manufacturing of reagents, consumables and diagnostic instruments. Its existing manufacturing infrastructure and proposed capacity expansion provide a platform to address increasing market demand and support higher value addition.
The Companys focus on reagents and consumables, expansion of its instrument portfolio, increasing installed base, product development and strengthening of its distribution network is expected to support recurring revenues and deepen its presence across the diagnostic ecosystem. Its portfolio
already spans clinical chemistry, haematology, molecular diagnostics, point-of-care testing, rapid tests and ELISA solutions.
Going forward, the Company intends to focus on increasing manufacturing capacity and utilisation, expanding its indigenous portfolio of reagents, kits and diagnostic instruments, strengthening its installed base and associated recurring consumables business, and expanding its domestic and international market presence. The Company also intends to continue investing in product development, technology and quality systems to support its long-term growth.
The Company remains focused on building a diversified and sustainable diagnostics business through indigenous manufacturing, technological collaborations, product expansion and increasing penetration across domestic and international markets.
RISKS AND CONCERNS
The Company operates in an industry exposed to regulatory, competitive, technological and operational risks. The key risks and concerns relevant to its business are as follows:
1. Regulatory and Product Quality Risk
The IVD industry is subject to regulatory approvals, licensing requirements and prescribed quality standards. Changes in regulatory requirements, delays in approvals or any product- quality issue may affect the Companys operations, product launches and market reputation.
2. Competition and Technological Risk
The industry is characterised by intense competition and rapid technological developments. The Company may face pricing pressure and the need for continuous investment in research, product development and technology to remain competitive.
3. Supply Chain and Cost Risk
Fluctuations in raw-material and component costs, dependence on certain imported inputs, foreign exchange movements and disruptions in global supply chains may affect the Companys costs and operating margins.
4. Working Capital and Execution Risk
The Companys operations require effective management of inventory and trade receivables. Further, manufacturing expansion and new product initiatives involve execution and capacity- utilisation risks, including delays in approvals or commercialisation.
The Company continuously monitors these risks and takes appropriate measures through quality controls, regulatory compliance, product diversification, supply-chain management and strengthening of internal processes.
INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY
The Company has established internal control systems and procedures commensurate with the size, nature and complexity of its business operations. The internal control framework is designed to provide reasonable assurance regarding the orderly and efficient conduct of business, safeguarding of assets, prevention and detection of errors and frauds, accuracy and completeness of accounting
records, timely preparation of reliable financial information and compliance with applicable laws and regulations.
The Companys internal control framework covers key operational and financial areas including procurement, inventory management, production, sales and receivables, payments, financial reporting, authorisation of transactions and statutory compliances. Appropriate processes and approval mechanisms are in place to ensure accountability, segregation of duties and effective monitoring of business activities.
During the year under review, the Company continued to strengthen its internal processes and control environment in line with the growth of its operations. The Company has also undertaken initiatives towards ERP implementation and strengthening of Internal Financial Controls and Internal Controls over Financial Reporting, with the objective of improving process automation, monitoring, reporting and overall control effectiveness.
The Management periodically reviews the adequacy and effectiveness of the internal control systems and takes corrective measures wherever required. The Statutory Auditors also consider the internal financial controls relevant to the preparation of the financial statements as part of their audit procedures. Based on the assessment undertaken, the Management is of the view that the Companys internal control systems are adequate and operating effectively and are commensurate with its present scale and nature of operations.
DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE
During FY 2025-26, the Company continued to strengthen its operational performance, with Revenue from Operations increasing to 341.16 crore from 313.07 crore in FY 2024-25, registering a growth of approximately 8.97%. The growth was primarily supported by a significant increase in the contribution from the Companys manufactured products business.
Revenue from manufactured products increased from 168.97 crore to 230.23 crore, representing a growth of approximately 36.25%. Consequently, manufactured products accounted for approximately 67.49% of total revenue from operations, compared with approximately 53.96% in the previous year. Revenue from traded products stood at 110.93 crore, compared with 144.10 crore in FY 2024-25, reflecting a decline of approximately 23.02%.
The improvement in the manufacturing-led business was also reflected in operating profitability. The segment result from manufactured products increased to 115.97 crore from 76.60 crore, while the segment result from traded products stood at 42.46 crore, compared with 45.08 crore in the previous year. Accordingly, the total segment result increased to 158.44 crore from 121.68 crore, registering growth of approximately 30.22%.
The Companys EBITDA increased to 98.05 crore from 70.55 crore, reflecting an improvement of approximately 38.97%, while EBITDA margin improved from approximately 22.53% to 28.69%. Profit before tax before exceptional/extraordinary items increased to 73.54 crore from 57.43 crore, and profit after tax before exceptional/extraordinary items increased to 56.71 crore from 36.18 crore.
The overall financial performance during the year reflects the Companys increasing focus on manufacturing, improved product mix, higher contribution from manufactured diagnostic products and operating efficiencies, which together supported a stronger improvement in profitability compared with the growth in revenue.
4 4 MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT, INCLUDING NUMBER OF PEOPLE EMPLOYED
Human resources continue to remain an important part of the Companys manufacturing, research and development, quality assurance, regulatory, sales and distribution operations. During FY 202526, the Company continued to focus on strengthening its workforce in line with the expansion of its manufacturing capabilities and business operations.
As at 31 March 2026, the Company had 357 permanent employees. The Company also engages personnel through third-party arrangements for certain manufacturing and operational activities, providing flexibility to meet its business and production requirements.
During the year, emphasis was placed on strengthening technical, manufacturing, R&D, quality, regulatory, sales and managerial capabilities to support the Companys growing operations. The Company continues to focus on employee development, skill enhancement, productivity and maintaining a professional and safe working environment.
The Company maintained cordial industrial relations during the year under review, and there were no material industrial disputes reported. The Management believes that a skilled, committed and adequately supported workforce will remain important to the Companys continued manufacturing expansion and business growth.
KEY FINANCIAL RATIOS:
| S. No. | Ratios | March 31, 2026 | March 31, 2025 | Change in % |
| 1. | Debtors Turnover | 5.76 | 6.85 | -15.91% |
| 2. | Inventory Turnover | 1.51 | 1.26 | 19.84% |
| 3. | Interest Coverage Ratio | 5.00 | 3.98 | 25.63% |
| 4. | Current Ratio | 1.64 | 1.48 | 10.81% |
| 5. | Debt Equity Ratio | 0.92 | 0.88 | 4.55% |
| 6. | Operating Profit Margin (%) | 28.69% | 22.53% | 27.34% |
| 7. | Net Profit Margin (%) | 16.60% | 11.55% | 43.72% |
The significant changes in the key financial ratios of the Company during the financial year ended March 31, 2026, as compared to the immediately preceding financial year, were primarily influenced by the Companys improved operating and financial performance, increased contribution from manufactured diagnostic products, favourable product mix, higher operating leverage and continued investment in manufacturing and business expansion.
During the year under review, the Company witnessed a significant shift towards its manufacturing- led business, with revenue from manufactured products increasing substantially and contributing a higher proportion of the Companys overall revenue. The improvement in manufacturing contribution, together with operating efficiencies and better product mix, supported an improvement in operating profitability and earnings during the year.
These operational and financial developments, together with changes in working-capital requirements and finance costs, influenced the Companys key financial ratios during FY 2025-26. The detailed explanations for changes exceeding 25% are set out below:
Unless otherwise stated, revenue and segment-wise figures in this section are presented on a standalone basis, while EBITDA, margins and financial ratios are presented on a consolidated basis
1. Interest Coverage Ratio - Increase of 25.63%
The Interest Coverage Ratio increased from 3.98 times in FY 2024-25 to 5.00 times in FY 2025-26, representing an improvement of 25.63%.
The improvement was primarily attributable to the Companys stronger operating and overall profitability during the year. Revenue from operations increased by approximately 9.13%, from c31,314.37 lakh in FY 2024-25 to 34,173.57 lakh in FY 2025-26, while EBITDA increased substantially by approximately 38.97%, from 7,055.05 lakh to 9,804.54 lakh.
The improvement in operating profitability was supported by the increased contribution from domestically manufactured products, favourable product mix, operating leverage and operating efficiencies. The resulting improvement in earnings relative to finance costs strengthened the Companys capacity to service its interest obligations.
2. Operating Profit Margin - Increase of 27.34%
The Operating Profit Margin increased from 22.53% in FY 2024-25 to 28.69% in FY 2025-26, representing an improvement of 27.34%.
The improvement was primarily attributable to the increasing contribution of manufactured diagnostic products, improved operating leverage, favourable product mix and operating efficiencies. EBITDA increased from 7,055.05 lakh to 9,804.54 lakh, while revenue from operations increased by approximately 9.13%.
The Companys manufactured products business recorded strong growth during the year, with manufactured-product revenue increasing by approximately 36.3% and accounting for approximately 67.4% of revenue from operations, compared with approximately 54.0% in the previous year. The increasing contribution from manufacturing therefore supported improvement in the Companys overall operating profitability.
3. Net Profit Margin - Increase of 43.72%
The Net Profit Margin increased from 11.55% in FY 2024-25 to 16.60% in FY 2025-26, representing an improvement of 43.72%.
The improvement was primarily attributable to the substantial increase in profitability during the year. Profit after tax before extraordinary items increased from 3,618.08 lakh in FY 202425 to 5,671.34 lakh in FY 2025-26, representing growth of approximately 56.75%, compared with approximately 9.13% growth in revenue from operations.
The improvement in net profitability reflects the combined impact of higher operating profitability, favourable product mix, increased contribution from manufactured products and improved earnings conversion during the year.
The Debtors Turnover Ratio, Inventory Turnover Ratio, Current Ratio and Debt Equity Ratio changed by less than 25% during FY 2025-26 and therefore do not constitute significant changes requiring separate explanation under the applicable disclosure threshold. The Debtors Turnover Ratio decreased from 6.85 times to 5.76 times, while Inventory Turnover
improved from 1.26 times to 1.51 times. The Current Ratio improved from 1.48 times to 1.64 times and the Debt Equity Ratio remained broadly stable at 0.92 times compared with 0.88 times in the previous year.
RETURN ON NET WORTH
The Return on Net Worth (RoNW) of the Company for the financial year ended March 31, 2026 stood at approximately 23.03%, as compared to 23.74% for the financial year ended March 31, 2025, representing a marginal decrease of approximately 2.99%.
The marginal movement in RoNW, notwithstanding the substantial improvement in profitability during the year, was primarily attributable to the combined effect of higher profitability and a significant strengthening of the Companys net worth during the year.
The Companys Profit After Tax before extraordinary items increased from 3,618.08 Lakhs in FY 2024-25 to 5,671.34 Lakhs in FY 2025-26, representing an increase of approximately 56.75%. The improvement in profitability was supported by growth in revenue, a favourable shift in product mix towards manufactured products, improved operating leverage and operating efficiencies, partly offset by higher finance costs and depreciation associated with the Companys capacity expansion.
At the same time, the Companys shareholders funds increased from 18,995.42 Lakhs as at March 31, 2025 to 24,619.20 Lakhs as at March 31, 2026, representing an increase of approximately 29.61%. The increase in shareholders funds was primarily attributable to the increase in share capital and accretion to reserves and surplus during the year.
Thus, the RoNW was influenced from both sides — the numerator, i.e. profitability, increased substantially, while the shareholders funds forming the equity base also increased significantly. The relatively higher growth in the equity base, compared with the movement in the RoNW denominator- adjusted profitability, resulted in the marginal moderation of RoNW from 23.74% to 23.03%.
The movement in RoNW should also be viewed in the context of the Companys manufacturing expansion and increased scale of operations during the year. Property, Plant and Equipment increased by approximately 121.7%, while finance costs and depreciation also increased by approximately 26.6% and 55.5%, respectively, reflecting investment in capacity expansion and the commissioning of additional manufacturing infrastructure.
Going forward, the Company remains focused on strengthening its manufacturing-led business, improving operating efficiencies, expanding its product portfolio, increasing capacity utilisation and maintaining disciplined financial management, which are expected to support sustainable improvement in profitability and returns over the medium to long term.
For and On behalf of Q- Line Biotech Limited
Saurabh Garg
Managing Director & Chairman DIN:02891621
Place: Lucknow
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.